Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals a mixed sentiment. While there are positive developments in product pipeline and strategic alignment with regulatory pathways, the lack of clear guidance on key metrics like fat loss and biomarker data, coupled with management's avoidance of direct answers, creates uncertainty. The Q&A section highlights cautious optimism but also reveals potential risks and uncertainties. Without a market cap context, it's challenging to predict a strong movement, thus a neutral stance is appropriate.
Key Financial Performance
Revenue (Q4 2025) $17.2 million, a decrease from $83.7 million in the prior year quarter. The decrease was due to revenue recognized upon the termination of the Takeda collaboration in October 2024, partially offset by increases in revenue recognized under the GSK collaboration.
Revenue (Full Year 2025) $42.7 million, a decrease from $108.3 million in 2024. The decrease was due to the same reasons as the quarterly revenue drop.
Research and Development Expenses (Q4 2025) $52.8 million, an increase from $44.6 million in Q4 2024. The increase was driven by advancing the INHBE program, RNA editing programs, and compensation-related expenses, including share-based compensation.
Research and Development Expenses (Full Year 2025) $182.8 million, an increase from $159.7 million in 2024. The reasons for the increase are the same as for the quarterly rise.
General and Administrative Expenses (Q4 2025) $20.9 million, an increase from $16.1 million in Q4 2024. The increase was primarily due to compensation-related expenses, including share-based compensation.
General and Administrative Expenses (Full Year 2025) $75.3 million, an increase from $59 million in 2024. The reasons for the increase are the same as for the quarterly rise.
Net Loss (Q4 2025) $53.2 million, compared to net income of $29.3 million in Q4 2024. The shift to a net loss was due to decreased revenue and increased expenses.
Net Loss (Full Year 2025) $204.4 million, compared to a net loss of $97 million in 2024. The increase in net loss was due to the same reasons as the quarterly loss.
Cash and Cash Equivalents (End of 2025) $602.1 million, sufficient to fund operations into Q3 2028. This does not include potential future milestone and other payments under the GSK collaboration.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
WVE-007 for Obesity: Designed to address obesity by targeting INHBE to lower serum activin E levels, improving body composition by reducing fat while preserving muscle. Demonstrated fat loss similar to semaglutide without muscle loss in Phase I trials. Phase IIa trials to begin in 2026.
WVE-006 for AATD: Targets alpha-1 antitrypsin deficiency (AATD) using RNA editing to correct mutant RNA transcripts. Demonstrated ability to restore AAT protein levels and address both lung and liver manifestations of the disease. Regulatory feedback expected in mid-2026.
WVE-008 for PNPLA3 I148M Liver Disease: RNA editing candidate targeting PNPLA3 variant linked to NASH pathology. Aims to restore PNPLA3 activity and improve liver health. CTA submission planned for 2026.
Obesity Treatment Market: Potential to shift the obesity treatment landscape with a once or twice yearly treatment that reduces fat and preserves muscle. Positioned as an add-on or maintenance therapy to incretins.
RNA Editing for Genetic Disorders: Expanding into genetic disorders like AATD and PNPLA3 I148M liver disease, addressing unmet needs in these markets.
Financial Position: Ended 2025 with $602.1 million in cash and cash equivalents, sufficient to fund operations into Q3 2028. Revenue impacted by termination of Takeda collaboration but offset by GSK collaboration milestones.
Research and Development: Increased R&D expenses driven by advancements in INHBE and RNA editing programs.
Focus on RNA Medicines: Strategic focus on accelerating development of WVE-007 for obesity and advancing RNA editing portfolio.
Collaborations: Progressing collaboration with GSK, with milestone payments contributing to financial stability. GSK selected a fourth program for development.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Feedback Delays: The company anticipates receiving regulatory feedback for WVE-006 in mid-2026, which could delay the accelerated approval pathway and impact the timeline for commercialization.
Clinical Trial Risks: The INLIGHT study for WVE-007 and RestorAATion-2 trial for WVE-006 are ongoing, and their success depends on achieving specific clinical endpoints. Any failure to meet these endpoints could adversely affect the company's strategic objectives.
Market Competition: The obesity treatment market is highly competitive, with established players like GLP-1s. WVE-007 must demonstrate clear advantages in efficacy, safety, and dosing frequency to gain market share.
Financial Sustainability: The company reported a net loss of $204.4 million for 2025 and is relying on its $602.1 million cash reserves to fund operations until Q3 2028. Any delays in achieving milestones or receiving collaboration payments could strain financial resources.
Supply Chain and Manufacturing Risks: The development and production of RNA-based therapies like WVE-007 and WVE-006 require specialized manufacturing processes. Any disruptions could delay clinical trials and commercialization.
Dependence on Collaborations: The company’s financial health is partially dependent on milestone payments from collaborations, such as the GSK partnership. Any changes or terminations in these agreements could impact revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
WVE-007 for Obesity: The company is advancing the development of WVE-007, targeting obesity treatment. The INLIGHT Phase I study showed promising results, including fat loss without muscle loss, supporting once or twice a year dosing. Phase IIa multi-dose trials are set to begin in the first half of 2026, focusing on individuals with higher BMI and comorbidities. Additional trials for WVE-007 as an incretin add-on and post-incretin maintenance therapy are planned for 2026.
WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD): The company is progressing with WVE-006, aiming to address AATD by restoring endogenous M-AAT protein levels and reducing mutant Z-AAT. Regulatory feedback on an accelerated approval pathway is expected by mid-2026. Data from the 400-mg multi-dose cohort of the RestorAATion-2 trial will be reported this quarter, with additional data from the 600-mg cohort expected in 2026.
WVE-008 for PNPLA3 I148M Liver Disease: The company is advancing WVE-008 for liver disease caused by the PNPLA3 I148M variant. A CTA submission is planned for 2026, targeting a first-in-human study to evaluate target engagement and early efficacy.
Duchenne Muscular Dystrophy (DMD): The company plans to submit an NDA for N531 in 2026, seeking accelerated approval for a monthly dosing regimen.
GSK Collaboration: The collaboration with GSK is progressing, with a fourth program selected for development. The company expects to continue receiving milestone payments in 2026 and beyond.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How closely does your regulatory strategy for AATD align with your competitor's biomarker-driven path, and have you had comparable alignment discussions with the FDA?
A:The regulatory strategy is aligned with the biomarker approach used by competitors and existing therapies for AATD. The company anticipates feedback by mid-2026 on a registrational pathway and is encouraged by recent FDA comments on plausible mechanism pathways for ATV.
Q:Has there been a change in the timeline for the 400-milligram multi and 600-milligram single data for INHBE, and will this data still be released?
A:The data is on track, with all patients dosed. Updates will be provided in Q1, and subsequent updates will follow. The company has over 100 patients in the study across multiple dose cohorts.
Q:What are your expectations for the confirmatory trial requirements for AATD and post-marketing requirements for full approval?
A:The company aims to align with the FDA on confirmatory trial requirements. They are focusing on an accelerated approval pathway for AATD patients and plan to establish pathways for both lung and liver labeling.
Q:Do you have an internal weight loss target for the forthcoming six-month data for 240 milligrams and three-month data for 400 milligrams to achieve the 5% weight loss target at 12 months?
A:The company expects continued trajectory down on the weight loss curve, with lean mass preservation and fat reduction. They aim to achieve a regulatory pathway for weight loss and emphasize the importance of addressing body composition for health outcomes.
Q:What are your thoughts on the safety profile and efficacy of INHBE compared to other activin pathways like ALK7?
A:The company sees a differentiated safety and efficacy profile for INHBE, with substantial fat loss and lean mass preservation. They emphasize the specificity of INHBE and its established benefits in clinical genetics and human studies.
Q:What treatment delta are you expecting for MRI-PDFF in your planned Phase II obesity trial?
A:The company sees a substantial opportunity for monotherapy in MASH, with potential for significant liver fat reduction. They aim to explore lipid level reductions and long-term cardiovascular benefits.
Q:Are you seeing similar fat loss to competitors with lower activin E knockdown, and do you have preclinical data showing better fat loss with higher knockdown?
A:The company has larger cohorts and long-term data showing durable activin E suppression. Preclinical data indicates a dose response, with higher knockdown leading to better fat loss.
Q:Will you share additional biomarker data related to inflammation or fibrosis in the upcoming INLIGHT update, and will the data be presented at a medical conference?
A:The company has not guided on conference presentations but will provide updates this quarter. Biomarker data is limited due to the healthy population in the study, but more opportunities will arise in Phase IIa with patients having comorbidities.
Q:What are your expectations for body fat reduction and AAT levels in upcoming readouts for 007 and 006?
A:For 007, the company expects continued fat reduction and lean mass stabilization. For 006, they aim to establish a therapeutic threshold for AAT levels and assess durability and time for potential quarterly or less frequent dosing.
Q:Would you expect 007 to affect muscles given its liver-directed nature, and how does it coexist with 008 over time?
A:007 is liver-directed with no expected impact on muscles. 008 targets genetic mutations causing liver diseases, offering a unique approach distinct from 007's focus on body composition and fat reduction.
Q:What are your expectations for 007's kinetics and the rate of fat loss, weight loss, and lean muscle mass change over the next six to nine months?
A:The company expects fat reduction and lean mass preservation to continue over time, with higher doses leading to more fat reduction. They aim to track these changes in both low and high BMI settings.
Q:How important is it to be the first to pivotal data for INHBE, and what will differentiate players in the activin E space?
A:The company believes being a leader in INHBE is crucial and highlights their differentiated chemistry and preclinical data. They see opportunities to sustain leadership and differentiate from competitors with unique efficacy and safety profiles.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about specific biomarker data for inflammation or fibrosis in the INLIGHT update, as well as detailed expectations for MRI-PDFF treatment delta in the Phase II obesity trial. They also did not provide clear guidance on the rate of fat loss and lean muscle mass change over the next six to nine months.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BMI comorbidities
GSK program
GalNAc AIMer
IIa portion
NASH
PNPLA liver
Phase IIa
SpiNA design
WVE PNPLA
activin dosing
acute phase
body composition
brake
collaboration GSK
compensation
composition fat
composition loss
control program
diet modification
dose engagement
fat muscle
fat obesity
improvement body
individual BMI
individual overweight
loss stabilization
mass improvement
mid
muscle loss
obesity study
phase response
placebo reduction
population fat
portion INLIGHT
program feedback
reduction fat
serum activin
WVE Transcript
Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call summary reveals a mixed sentiment. While there are positive developments in product pipeline and strategic alignment with regulatory pathways, the lack of clear guidance on key metrics like fat loss and biomarker data, coupled with management's avoidance of direct answers, creates uncertainty. The Q&A section highlights cautious optimism but also reveals potential risks and uncertainties. Without a market cap context, it's challenging to predict a strong movement, thus a neutral stance is appropriate.
Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call summary indicates a mix of positive and cautious elements. While there are promising developments in product pipelines and strategic plans, there are also uncertainties, particularly in the obesity program and AATD study. The Q&A highlighted management's avoidance of specifics, which may raise concerns. No strong catalysts like partnerships or record revenues were mentioned, and the strategic plan lacks immediate financial impact. The absence of market cap data limits assessment of stock sensitivity, but overall sentiment leans towards neutral given the balanced positives and uncertainties.
WVE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
